| 产品名称: | Human herpesvirus 3 |
|---|---|
| 商品货号: | TS213774 |
| Classification: | Herpesviridae, Varicellovirus |
| Agent: | Human herpesvirus 3 |
| Strain: | Oka |
| Common Name: | Varicella zoster virus |
| Applications: | Virucide testing In vitro infectivity assay Antiviral Studies Spiking studies ELISpot Assay Virus neutralization assay Virus ultrastructural studies Immunological-based assays PCR-based assay validation Research and development Assay development Vaccine development |
| Biosafety Level: | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format: | frozen 1.0 mL per vial |
| Storage Conditions: | Vapor phase of liquid nitrogen |
| Images: | |
| Comments: | Live, attenuated vaccine strain. Thermosensitive compared with other wild type strains. Depositor screened by Neurovirulence safety test, and result was compliant. |
| Effect on Host: | CPE, refractile rounding and degenration |
| Recommended Host: | MRC-5 cells (ATCC® CCL-171™) |
| Growth Conditions: | Temperature: 37°C Recommendations for Infection: Plate cells 16-24 hours prior to infection and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.01). Adsorb 1-2 hours at 37°C in a humidified x% CO2 atmosphere. End adsorption by adding virus growth medium. Replace virus growth medium at one day post-inoculation to remove DMSO from the culture. Harvest by removing culture medium and adding cell dissociation buffer. Dilute in freeze medium containing a final concentration of 7% DMSO and preserve with a controlled-rate freeze (1°C/minute). Incubation: 3-4 days at 37°C in a humidified 5% CO2 atmosphere, until CPE is progressed through 60% of the monolayer. |
| Source: | Y Oyabu, The Research Foundation for Microbial Diseases of Osaka University |
| References: | Takahashi M, et al. Development of a live attenuated varicella vaccine. Biken J. 18: 25-33, 1975. PubMed: 167707 |